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Abstract
Purpose Cardiac surgery and conventional extracorporeal circulation (CECC) impair the bioavailability of drugs administered by
mouth. It is not known whether miniaturized ECC (MECC) or off-pump surgery (OPCAB) affect the bioavailability in similar
manner. We evaluated the metoprolol bioavailability in patients undergoing CABG surgery with CECC, MECC, or having
OPCAB.
Methods Thirty patients, ten in each group, aged 44–79 years, scheduled for CABG surgerywere administered 50mgmetoprolol
by mouth on the preoperative day at 8–10 a.m. and 8 p.m., 2 h before surgery, and thereafter daily at 8 a.m. and 8 p.m. Blood
samples were collected up to 12 h after the morning dose on the preoperative day and on first and third postoperative days.
Metoprolol concentration in plasma was analyzed using liquid chromatography-mass spectrometry.
Results The absorption of metoprolol was markedly reduced on the first postoperative day in all three groups, but recovered to
the preoperative level on the third postoperative day. The geometric means (90% confidence interval) of AUC0–12 on the first and
third postoperative days versus the preoperative day were 44 (26–74)% and 109 (86–139)% in the CECC-group, 28 (16–50)%
and 79 (59–105)% in the MECC-group, and 26 (12–56)% and 96 (77–119)% in the OPCAB-group, respectively. Two patients in
the CECC-group and two in the MECC-group developed atrial fibrillation (AF). The bioavailability and the drug concentrations
of metoprolol in patients developing AF did not differ from those who remained in sinus rhythm.
Conclusion The bioavailability of metoprolol by mouth was markedly reduced in the early phase after CABG with no difference
between the CECC-, MECC-, and OPCAB-groups.
Keywords Metoprolol . Pharmacokinetics . Area under the curve . Atrial fibrillation . Postoperative . Coronary artery bypass
grafting surgery
Atrial fibrillation (AF) is the most common arrhythmia to
occur after cardiac surgery. The incidence of AF has been
reported to range between 20 and 45% after coronary artery
bypass graft (CABG) surgery and is even higher after valve
and combined valve and bypass surgery [1–8]. Postoperative
AF is associated with the risk of mortality and morbidity from
stroke, heart failure, myocardial infarction, thromboembo-
lism, bleeding from anticoagulation, hospital readmission,
and increased costs [5, 9–11].
Beta-blockers reduce the incidence of AF after cardiac sur-
gery [12–16]. Thus, the European Society of Cardiology
(ESC) guidelines recommend routine preoperative and early
postoperative beta-blocker therapy after cardiac surgery
CABG [17]. Metoprolol is a commonly used beta-blocker. It
is metabolized primarily by hepatic cytochrome P450 2D6
(CYP2D6) that is highly polymorphic [18]. The combined
prevalence of extreme phenotypes, i.e., poor and ultrarapid
metabolizers, is 10–20% among the Caucasians. A recent
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meta-analysis showed that the poor metabolizers have 13-fold
area under the concentration-time curve (AUC) compared to
ultrarapid metabolizers [18]. CYP2D6 is not inducible, but it is
inhibited by several drugs.
However, in spite of beta-blockers, the risk of postopera-
tive AF remains high, about 20% [14]. Recently, it has been
shown that intravenous beta-blocker is more efficient than
beta-blocker by mouth in the prevention of postoperative AF
[19]. This has been postulated to be due to reduced absorption
of swallowed beta-blockers as a result of diminished visceral
blood flow, delayed gastrointestinal motility, peri- and post-
operative use of opioids, and inflammatory response caused
by extracorporeal circulation (ECC) [20].
New techniques, such as miniaturized ECC (MECC), have
been developed to reduce blood-air and blood-artificial mate-
rial contact and, thus, inflammatory response compared to
conventional ECC (CECC) [21–23]. In addition, an increasing
number of CABG procedures are performed without any ECC
(OPCAB) aiming to less surgical trauma and even less inflam-
matory reaction than with CECC or MECC [24, 25].
In this study, our hypothesis was that the surgical trauma to
the body is less with MECC and OPCAB than that with
CECC, and as the result, the gastrointestinal function is less
disturbed and the absorption of metoprolol by mouth is pre-
served. To test this hypothesis, we planned a three-arm phar-
macokinetic study where the primary outcome measure was
the absorption of metoprolol by mouth on the preoperative,
first and third postoperative days in patients scheduled for
CABG with CECC, MECC, or OPCAB.
Material and methods
Patients
The study population consisted of 30 patients, aged between
44 and 79 years, who were scheduled for elective CABG
surgery in the Kuopio University Hospital between
November 2012 and March 2015.
The patients were given oral and written information of the
trial protocol, and they all provided written consent. The study
protocol was approved by the Research Ethics Committee of
the Hospital District of Northern Savo, Kuopio, Finland (ref.
11// 2012), Finnish Medicines Agency was notified (ref. 63 //
2012), and it was registered in the European Clinical Trials
Database (Eudra CT: 2012-001983-31) and was conducted in
accordance with the Declaration of Helsinki. The study had
institutional approval.
All patients aged between 18 and 80 years of age were
included if they had no contraindication to metoprolol.
Patients already using metoprolol were excluded, as were pa-
tients with a previous surgery of upper gastrointestinal tract,
disease or any other condition that could interfere with the
gastric absorption, moderate or severe hepatic or renal impair-
ment, and patients having concomitant CYP2D6 inhibitors,
such as diltiazem, fluoxetine, and paroxetin, in use. A total
of 32 patients agreed were included, but two patients were
withdrawn from the study: one due to postoperative hypoten-
sion and one due to logistic reasons. Thus, the final population
consisted of 30 patients, all of who had a clinical indication for
beta-blocker (Table S1—available in the BElectronic supple-
mentary material^).
Metoprolol administration
Patients arrived to the hospital on the day before surgery. A
total of 23 patients were on beta-blockers (bisoprolol). They
were not given the compound during the time they were on
metoprolol. They were asked to fast for at least 2 h before the
metoprolol administration. Each patient was given a 50-mg
tablet of metoprolol tartrate (Metoprolin Ratiopharm;
Merckle GmbH, Blaubeuren, Germany) with a glass of water
(150 mL) at 8–10 a.m. After this, they were asked to remain in
an upright position for at least 30 min, either sitting on a chair
or walking around the ward. Fasting was continued for 4 h
after the test drug administration, and at noon, the patients
were served a light meal. The patients were provided with
two additional doses of metoprolol 50 mg before surgery: at
8 p.m. on the day before the surgery and at 6 a.m. on the day of
the operation. Metoprolol administration was continued from
the first postoperative morning: 50-mg tablets were adminis-
tered by mouth at 8 a.m. and at 8 p.m.
Blood samples
Blood samples (3mL)were obtainedwith an indwelling catheter
inserted in an antecubital vein at baseline (before drug adminis-
tration) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 h after the
morning dose on the preoperative day and on the first and the
third postoperative days. The baseline sample was obtained be-
fore the 8 a.m. administration ofmetoprolol, and the 12-h sample
was obtained before the 8 p.m.metoprolol administration. Blood
was collected into EDTA tubes, and plasma was obtained within
20 min of collection by centrifugation at 2100 g for 10 min at +
20 °C. The separated plasma was stored at − 76 °C until analysis
performed in two slots at the laboratory in the Department of
Forensic Medicine, University of Helsinki, Helsinki, Finland.
Arterial blood pressure and heart rate and rhythm were recorded
after each blood sample.
Outcome measures
The primary outcome measure was AUC from time 0 to 12 h
(AUC0–12) on the first and third postoperative days compared
to that on the preoperative day. The secondary outcomes were
the peak concentration (Cmax), time to peak concentration
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(Tmax), and elimination half-life (T1/2). For clinical outcome
measure, we used the incidence of postoperative AF and for
safety parameter adverse events (AE).
Anesthetic management and extracorporeal
circulation
Before surgery, the patients received premedication by mouth,
diazepam 10–15 mg. Nitrides, statins, cortisone, and medica-
tion for chronic pulmonary disease were given from their drug
list. Metoprolol was given according to the study protocol. A
standardized anesthesia protocol was used for each patient
(Appendix 1—Electronic supplementary material), and for
ECC, customized perfusion sets were used (Appendix 2—
Electronic supplementary material).
Plasma metoprolol concentrations
The present method is a modification of the method published
earlier [20] and involves minor updates in instrument analysis,
while the extraction procedure was unchanged. The basic val-
idation results remained the same, including the lower limit of
quantification (LOQ) 1 μg/L (Appendix 3—Electronic sup-
plementary material).
Pharmacokinetic parameters
Pharmacokinetic parameters (AUC0–12,Cmax, Tmax, T1/2) were
calculated based on noncompartmental analysis using the
Phoenix WinNonlin version 6.3 software (Certara,
Princeton, NJ, USA). AUC0–12 was calculated using the linear
trapezoidal rule. T1/2 was determined only when there was a
clear log-linear terminal phase.
Statistics
Sample size calculation was based on our earlier study in
which the preoperative metoprolol AUC0–12 in CECC patients
was 14.5 mg·min/L and that on the first postoperative day
7.8 mg·min/L (SD 5.4 mg·min/L), respectively [20]. A sample
size of 13 patients per group would provide a study power of
80% to detect a difference between groups at a significance
level of 0.05.
Within each group, paired analysis between the first post-
operative day and the preoperative day and between the third
postoperative day and the preoperative day were done for
AUC0–12 and Cmax using two one-sided t tests (paired-sample
equivalence test). The hypothesis pair was tested with type I
error rate of 5% for each variable and study day separately, and
the ratio of geometric means and its 90% confidence interval
(CI) are reported. The analyses were performed with SAS®
version 9.4 for Windows (SAS Institute Inc., Cary, NC, USA).
The between-group differences in the preoperative day and
the first and third postoperative day AUC0–12, Cmax, and T1/2
values (each day separately; T1/2 only on the preoperative day)
were analyzed with Kruskal-Wallis test and post hoc compar-
ison between patients with AF and no-AF with Mann-
Whitney test using the SigmaPlot version 13.0 software
(Systat Software, Inc., San Jose, CA, USA). The Tukey test
was used in all pair-wise comparisons.
Differences were regarded as statistically significant if the
P value was less than 0.05. Descriptive statistics of the data are
expressed as the number of cases and mean with standard
deviation or median with minimum and maximum where
appropriate.
Results
Due to logistical reasons, a total of 32 patients were enrolled
and after two exclusions 30 patients were included in the final
analysis, 10 patients in each group. The patients’ characteris-
tics are presented in Table 1. Data was not collected on the
third postoperative day in three patients, one patient from each
study group. Thus, we had 30 full data sets for the preopera-
tive day and first postoperative day and 27 data sets for the
third postoperative day. The third postoperative day data from
one patient in the CECC-group were excluded from the anal-
ysis, since the metoprolol concentration in the baseline sample
was 96% of the Cmax observed later on that day indicating
major carryover from the previous doses. In other subjects
the median and mean carryover percentages were 8 and
11%, respectively, meaning that the carryover did not affect
the major findings of our study. The carryover was negligible
in the baseline samples on the first postoperative day (the
previous dose was taken 24–26 h earlier).
Metoprolol bioavailability
On the preoperative day, the pharmacokinetic parameters were
similar in all three groups (Table 1). In contrary to our study
hypothesis, there were no significant differences in AUC0–12
and Cmax values between the study groups on the first or third
postoperative days (Table 1, Figs. 1, 2, and 3). Significant
interindividual variation was observed in all three study
groups.
Within each group, the geometric mean of AUC0–12 on the
first postoperative day was 26–44% of the preoperative value,
and the upper limits of 90% CI (50–74%) were significantly
below 100%, respectively (Table 2). On the third postopera-
tive day, AUC0–12 had returned to 79–109% of the preopera-
tive values, and 100% was always included in the 90% CI,
respectively. A similar pattern was seen inCmax, except that in
the CECC-group, the whole 90% CI was slightly above 100%
on the third postoperative day. On the first postoperative day,
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Tmax occurred later than in other study days in all study groups
(Table 1). On the third postoperative day, there were two very
late Tmax values, one at 720min in the CECC-group and one at
480 min in the OPCAB-group, respectively (Figs. 1 and 3).
Preoperatively, six patients in the CECC-group, six in the
MECC-group, and nine in the OPCAB-group had Cmax above
the lower therapeutic reference value of 35 μg/L for metopro-
lol. On the first postoperative day four in the CECC-group,
two in the MECC-group and three in the OPCAB-group had
Cmax ≥ 35 μg/L. On the third postoperative day, Cmax values
had resumed to the preoperative levels in all three groups,
seven out of nine, six out of nine, and eight out of nine had
Cmax ≥ 35 μg/L in the CECC-group, MECC-group, and
OPCAB-group, respectively.
Clinical outcome
No patients in the OPCAB-group developed postoperative
AF, whereas two patients in the CECC-group and two in the
MECC-group presented with postoperative AF. In a post hoc
analysis, it appeared that the AUC0–12 and Cmax and Tmax
values of the four patients with postoperative AF did not differ
from those in 23 patients who recovered without AF
(Table S2—available in the BElectronic supplementary
material^). Preoperatively, all four patients with AF had
Cmax ≥ 35 μg/L for metoprolol. On the first postoperative
day, three out of four patients and on the third postopera-
tive day all four patients with postoperative AF had Cmax ≥
35 μg/L, respectively (Table 2).
None of the patients died during the 30-day follow-up after
cardiac surgery. Two patients, one in the CECC-group and one
in the OPCAB-group, developed postoperatively respiratory
insufficiency and were diagnosed to have pneumonia. They
were readmitted to the intensive care unit, but thereafter, their
recovery was uneventful. One patient in the OPCAB-group
had protracted nausea on the first postoperative day, his
AUC0–12 were 18,850, 3890, and 16,230 min·μg/L and Cmax
74, 7, and 59 μg/L on preoperative, first, and third
Table 1 Pharmacokinetic
parameters for 50-mg metoprolol
tablet after CABG in different
treatment groups
Group Study day Number AUC0–12 (min·μg/L) Cmax (μg/L) Tmax (min) T1/2 (min)
CECC Preoperative 10 18,500 ± 15,800 65 ± 54 94 [58–180] 226 ± 54
First postop. 10 9820 ± 11,400 37 ± 44 151 [27–732]
Third postop. 8 26,300 ± 26,300 89 ± 64 94 [60–712]
MECC Preoperative 10 24,400 ± 24,400 98 ± 91 74 [60–154] 243 ± 77
First postop. 10 7300 ± 8060 26 ± 29 602 [85–745]
Third postop. 9 17,800 ± 19,200 63 ± 40 89 [30–255]
OPCAB Preoperative 10 19,900 ± 9860 78 ± 44 80 [30–154] 189 ± 35
First postop. 10 8600 ± 8440 27 ± 27 359 [90–723]
Third postop. 9 19,100 ± 7910 64 ± 31 180 [60–483]
Data are arithmetic means ± SD, except median [minimum-maximum] for Tmax























































































Fig. 1 Plasma concentrations of metoprolol in the CECC-group in the
three study days
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postoperative days, respectively. In the MECC-group, one pa-
tient had postoperative fever, one had subcutaneous emphy-
sema, one had hypertension, and one had excessive drowsi-
ness on the first postoperative day.
Discussion
The main findings of our study were, first, that the relative
bioavailability of metoprolol reduced by 50–75% on the first
postoperative day compared to that observed preoperatively;
second, it resumed back to preoperative on the third postop-
erative day; and third, CECC, MECC, and OPCAP did not
differ from each other with respect to metoprolol bioavailabil-
ity. Our data is consistent to that reported earlier [20],
indicating that to achieve sufficient blood concentration of
metoprolol in early phase after CABG surgery, it should be
administered intravenously.
The pathophysiology of postoperative AF is not fully un-
derstood. On possible mechanism is systemic inflammatory
response caused by ECC [26, 27]. It is assumed to render the
heart vulnerable to arrhythmias. In addition, ECC has been
suggested to impair drug absorption from the gastrointestinal
tract resulting in reduced bioavailability of drugs, including
beta-blockers. Indeed, Valtola et al. [20] reported that the bio-
availability of orally administered metoprolol was markedly
reduced during the early recovery phase after CABG. This is
supported also by the study by Halonen et al. [19] in which the
incidence of postoperative AF was significantly lower in pa-
















































































































































































Fig. 3 Plasma concentrations of metoprolol in the OPCAB-group in the
three study days
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Evolution of the cardiopulmonary bypass has emerged new
techniques such as MECC to reduce the inflammatory re-
sponse follow cardiac surgery [21–23]. Reducing the surface
area of the circuit and removing the blood-air interface poten-
tially offers several benefits compared to CECC including
reduced hemodilution, postbypass coagulopathy, and inflam-
matory response [28, 29]. Extracorporeal circulation can be
completely avoided by using OPCAP technique. Indeed, there
is some evidence that that OPCAB could minimize the risk of
inflammatory response and gastrointestinal complications fol-
lowing cardiac surgery [30–32]. In the light is the above, it
was of surprise that in our study the method of ECC was not
related to the bioavailability of metoprolol; AUC0–12, Cmax,
and Tmax did not differ between patients undergoing CABG
with CECC, MECC, or OPCAB methods. This suggests that
systemic inflammation induced by ECC is not the only mech-
anism influencing metoprolol bioavailability.
Metoprolol tartrate is rapidly and almost completely
absorbed from the GI tract indicating about 50% first-pass
metabolism [32]. It is poorly absorbed from the stomach,
whereas it is well absorbed from the small intestine and the
colon [19]. In healthy volunteers, following a single adminis-
tration by mouth, metoprolol appears in the plasma within
10 min and Cmax is reached within 90 min [32].
Accordingly, in our study at baseline, Cmax were reached in
74–94 min, whereas on the first postoperative day, they
prolonged to 151–602 min indicating slowing down of meto-
prolol absorption rate. Gastric emptying rate regulates the ab-
sorption rate of metoprolol from the small intestine. The rate,
but not the extent of metoprolol absorption, is increased by the
presence of food in the gastrointestinal tract [33, 34]. Opioids
are known to inhibit down gastric emptying and intestinal
motility [35]. Even on the third postoperative day, two sub-
jects (of 27) had very late Tmax values (480 and 720 min),
suggesting that the gastrointestinal function had not recovered
completely in these subjects [20]. In our study, all patients
were given opioids for postoperative pain. This is plausibly
one of the mechanism responsible for the reduced metoprolol
absorption after CECC, MECCV, but also OPCAB surgery.
The plasma metoprolol concentrations in our study were
similar to those reported earlier [20, 36]. In addition, we found
a large interindividual variation in the metoprolol absorption;
the lowest and highest Cmax were 10 and 290 μg/L with 29-
fold difference. The difference between lowest and highest
AUC0–12 was even larger, 42-fold. In line with us, Valtola
et al. [20] and Lundborg and Steen [36] reported a high, 15-
to 31-fold interindividual variation in the Cmax after a single
50-mg dose of metoprolol bymouth. Both studies reported the
lowest plasma metoprolol concentration to be far below the
lower level of the therapeutic range (35 μg/L). The lowest
Cmax in their studies were 3 and 14 μg/L, respectively, and
in the present study, it was 10 μg/L. The highest Cmax were
also similar, 140, 210, and 290 μg/L, respectively [20, 36].
The high interindividual variation can be explained by the
metabolism of metoprolol. Although metoprolol tartrate is al-
most completely absorbed from the gastrointestinal tract, it
undergoes significant first-pass metabolism, and thus, the bio-
availability is about 50% [32]. Metoprolol is metabolized pre-
dominantly by CYP2D6, and as there is high interindividual
variation in the CYP2D6 activity, about 2–5% of the
Caucasians being ultrarapid metabolizers and 5–10% slow
metabolizers that results in significant variation in the interin-
dividual exposure to metoprolol administered by mouth [18,
37]. In our study, the high values for the subject 6 in the
MECC-group on the preoperative day (Cmax 185 μg/L,
AUC0–12 84,900 min·μg/L, T1/2 7.0 h) are similar to those of
poor metabolizers in a recent meta-analysis [18]. Additionally,
on the preoperative day, several subjects in our study had
Table 2 Pharmacokinetic parameters for 50-mg metoprolol tablet after CABG in different treatment groups
Group Study day Number AUC0–12 geometric mean Cmax geometric mean
Value (min·μg/L) vs preop. day (%) Value (μg/L) vs preop. day (%)
CECC Preoperative 10 11,700 – 44.3 –
First postop. 10 5130 44 (26–74) 21.5 49 (30–78)
Third postop. 8 14,200 109 (86–139) 59.9 127 (103–157)
MECC Preoperative 10 16,000 – 62.8
First postop. 10 4470 28 (16–50) 15.8 25 (13–47)
Third postop. 9 12,700 79 (59–105) 52.0 82 (55–122)
OPCAB Preoperative 10 17,800 – 68.9
First postop. 10 4610 26 (12–56) 14.7 21 (9–50)
Third postop. 9 17,800 96 (77–119) 57.1 79 (56–112)
Data are geometric means of pharmacokinetic parameters and their postoperative versus preoperative comparison is the ratio of the means (90%
confidence interval) using n according to the postoperative day
CABG coronary artery bypass surgery
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values similar to those of ultrarapid metabolizers in the same
meta-analysis [18]. The lack of CYP2D6 genotyping is a lim-
itation in our study. However, it does not weaken our conclu-
sions on between-day comparison within each group, since
the patients acted as their own controls.
In our study, four patients (13%) developed AF. This is in
line that with earlier reports on patients with CABG [18]. AF
developed in one fifth of patients in the CECC-group and in
the MECC-group whereas in none of the patients treated with
OPCAB. However, our study was unpowered to evaluate the
differences in the AF incidence between the groups. On the
other hand, it was of surprise that the bioavailability of meto-
prolol assessed with AUC0–12 and Cmax tended to be higher in
the four AF patients compared to non-AF patients.
In conclusion, the bioavailability of metoprolol by was
markedly reduced in the early phase after CABG with no
difference between the CECC-, MECC-, and OPCAB-groups.
One third of the patients with ECC developed postoperative
AF but none in the OPCAB-group. As the pharmacokinetic
parameters were similar in those with AF and no-AF, in fur-
ther studies, other parameters that may explain the difference
should be evaluated.
Funding This study was funded by the governmental VTR-grant by the
Hospital District of Northern Savo, Kuopio, Finland and Olvi Säätiö,
Iisalmi, Finland.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institu-
tional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual
participants included in the study.
References
1. SvedjeholmR, Håkanson E (2000) Predictors of atrial fibrillation in
patients undergoing surgery for ischemic heart disease. Scand
Cardiovasc J 34:516–521
2. Zaman AG, Archbold A, Helft G, Paul EA, Gurzen NP, Mills PG
(2000)Atrial fibrillation after coronary artery bypass surgery: amodel
for preoperative risk stratification. Circulation 101:1403–1408
3. Mahoney EM, Thompson TD, Veledar E, Williams J, Weintraub
WC (2002) Cost-effectiveness of targeting patients undergoing car-
diac surgery for therapy with intravenous amoidarone to prevent
atrial fibrillation. J Am Coll Cardiol 40:737–745
4. Majahalme S, KimMH, Bruckman D, Tarkka M, Eagle KA (2002)
Atrial fibrillation after coronary surgery: comparison between dif-
ferent health care systems. Int J Cardiol 82:209–218
5. Lahtinen J, Biancari F, Salmela E, Mosorin M, Satta J, Rainio P,
Rimpiläinen J, Lepojärvi M, Juvonen T (2004) Postoperative atrial
fibrillation is a major cause of stroke after on-pump coronary artery
bypass surgery. Ann Thorac Surg 77:1241–1244
6. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD,
Barash PG, Hsu PH, Mangano DT, Investigators of the Ischemia
Research and Education Foundation, Multicenter Study of
Perioperative Ischemia Research Group (2004) A multicenter risk in-
dex for atrial fibrillation after cardiac surgery. JAMA 291:1720–1729
7. Ahlsson AJ, Bodin L, Lundblad OH, Englund AG (2007)
Postoperative atrial fibrillation is not correlated to C-reactive pro-
tein. Ann Thorac Surg 83:1332–1337
8. Arsenault KA, Yusuf AM, Crystal E et al (2013) Interventions for
preventing post-operative atrial fibrillation in patients undergoing
heart surgery. Cochrane Database Syst Rev 1:Cd003611
9. Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE,
Henderson WG, Tarazi R, Shroyer AL, Sethi GK, Grover FL,
Hammermeister KE (1997) Atrial fibrillation after cardiac surgery:
a major morbid event? Ann Surg 226:501–513
10. Hakala T, Pitkänen O, Hippeläinen M (2002) Feasibility of
predicting the risk of atrial fibrillation after coronary artery bypass
surgery with logistic regression model. Scand J Surg 91:339–344
11. Steinberg BA, Zhao Y, He X et al (2014) Management of postop-
erative atrial fibrillation and subsequent outcomes in contemporary
patients undergoing cardiac surgery: insights from the Society of
Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. Clin
Cardiol 37:7–13
12. Andrews TC, Reimond SC, Berlin JA, Antman EM (1991)
Prevention of supraventricular arrhythmias after coronary artery
bypass surgery. A meta-analysis of randomized trials. Circulation
84:236–244
13. Kowey PR, Taylor JE, Rials SL, Marinchak RA (1992) Meta-
analysis of the effectiveness of prophylactic drug therapy in
preventing supraventriculat arrhythmias early after coronary artery
bypass grafting. Am J Cardiol 69:963–965
14. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S (2002)
Intervention on prevention of postoperative atrial fibrillation in patients
undergoing heart surgery. A meta-analysis. Circulation 106:75–80
15. Wurdeman RL, Mooss AN, Mohiuddin SM, Lenz TL (2002)
Amiodarone vs sotalol as prophylaxis against atrial fibrillation/
flutter after heart surgery. A meta-analysis. Chest 121:1203–1210
16. Zimmer J, Pezzullo J, Choucair W, Southard J, Kokkinos P, Karasik
P, Greenberg MD, Singh SN (2003) Meta-analysis of antiarrhyth-
mic therapy in the prevention of postoperative atrial fibrillation and
the effect on hospital length of stay, costs, cerebrovascular acci-
dents, and mortality in patients undergoing cardiac surgery. Am J
Cardiol 91:1137–1140
17. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B,
Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G,
Manolis AS, Oldgren J, Popescu BA, Schotten U, van Putte B,
Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W,
Carerj S, Casselman F, Coca A, de Caterina R, Deftereos S,
Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B,
Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A,
McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva
I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, van Gelder IC,
Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016
ESC guidelines for the management of atrial fibrillation developed
in collaboration with EACTS. Eur Heart J 37:2893–2962
18. Blake CM, Kharasch ED, Schwab M, Nagele P (2013) A meta-
analysis of CYP2D6 metabolizer phenotype and metoprolol phar-
macokinetics. Clin Pharmacol Ther 94:394–399
19. Halonen J, Hakala T, Auvinen T et al (2006) Intravenous adminis-
tration ofmetoprolol is more effective than peroral administration in
the prevention of atrial fibrillation after cardiac surgery. Circulation
114(suppl):I1–I4
Eur J Clin Pharmacol (2018) 74:785–792 791
20. Valtola A, Kokki H, Gergov M, Ojanperä I, Ranta VP, Hakala T
(2007) Does coronary artery bypass surgery affect metoprolol bio-
availability. Eur J Clin Pharmacol 63:471–478
21. Remadi JP, Rakotoarivello Z, Marticho P, Trojette F, Benamar A,
Poulain H, Tribouilloy C (2004) Aortic valve replacement with the
minimal extracorporeal circulation (Jostra MECC system) versus
standard cardiopulmonary bypass: a randomized prospective trial.
J Thorac Cardiovasc Surg 128:436–441
22. Kiaii B, Fox S, Swinamer SA, Rayman R, Higgins J, Cleland A,
Fernandes P, MacDonald J, Dobkowski WB, Stitt LW, Novick RJ,
Singh B, Bureau Y, Summers K (2012) The early inflammatory
response in a mini-cardiopulmonary bypass system: a prospective
randomized study. Innovations (Phila) 7:23–32
23. Nguyen BA, Fiorentino F, Reeves BC et al (2016) Mini bypass and
proinflammatory leukocyte activation: a randomized controlled tri-
al. Ann Thorac Surg 101:1454–1463
24. Koivisto SP, Wistbacka JO, Rimpiläinen R, Nissinen J, Loponen P,
Teittinen K, Biancari F (2010) Miniaturized versus conventional
cardiopulmonary bypass in high-risk patients undergoing coronary
artery bypass surgery. Perfusion 25:65–70
25. Harling L, Punjabi PP, Athanasiou T (2011) Miniaturized extracor-
poreal circulation vs. off-pump coronary artery bypass grafting:
what the evidence shows? Perfusion 26(suppl 1):40–47
26. Hall RI, Smith MS, Rocker G (1997) The systemic inflammatory
response to cardiopulmonary bypass: pathophysiological, therapeu-
tic, and pharmacological considerations. Anesth Analg 85:766–782
27. Wan S, LeClerc JL, Vincent JL (1997) Inflammatory response to
cardiopulmonary bypass: mechanisms involved and possible thera-
peutic strategies. Chest 112:676–692
28. Zangrillo A, Garozzo FA, Biondi-Zoccai G, Pappalardo F, Monaco
F, Crivellari M, Bignami E, Nuzzi M, Landoni G (2010)
Miniaturized cardiopulmonary bypass improves short-term
outcome in cardiac surgery: a meta-analysis of randomized con-
trolled studies. J Thorac Cardiovasc Surg 139:1162–1169
29. Benedetto U, Angeloni E, Refice S, Capuano F, Goracci M,
Roscitano A, Sinatra R (2009) Is minimized extracorporeal circu-
lation effective to reduce the need for red blood cell transfusion in
coronary artery bypass grafting? Meta-analysis of randomized con-
trolled trials. J Thorac Cardiovasc Surg 138:1450–1453
30. Croome KP, Kiaii B, Fox S et al (2009) Comparison of gastrointes-
tinal complications in on-pump versus off-pump coronary artery
bypass grafting. Can J Surg 52:125–128
31. Emmiler M, Yaveri A, Koçoğullari CU, Ela Y, Şahin DA, Sivaci
RG, Cekirdekci A (2009) Gastrointestinal ischemia related mortal-
ity in patients undergoing off- or on-pump coronary artery bypass
grafting. Heart Surg Forum 12:E79–E84
32. Regårdh C-G, Johnsson G (1980) Clinical pharmacokinetics of
metoprolol. Clin Pharmacokinet 5:557–569
33. Godbillon J, Evard D, Vidon N et al (1985) Investigation of drug
absorption from the gastrointestinal tract of man. III. Metoprolol in
the colon. Br J Clin Pharmacol 19(Suppl 2):113–118
34. Jobin G, Cortot A, Godbillon J, al e (1985) Investigation of drug
absorption from the gastrointestinal tract of man. I. Metoprolol in
the stomach, duodenum and jejunum. Br J Clin Pharmacol
19(Suppl 2):97–105
35. Heyland DK, Tougas G, King D, Cook DJ (1996) Impaired gastric
emptying in mechanically ventilated, critically ill patients. Intens
Care Med 22:1339–1344
36. Lundborg P, Steen B (1976) Plasma levels and effect on heart rate
and blood pressure of metoprolol after acute oral administration in
12 geriatric patients. Acta Med Scand 200:397–402
37. Fux R, Mörike K, Pröhmer AM et al (2005) Impact of CYP2D6
genotype on adverse effects during treatment with metoprolol: a
prospective clinical study. Clin Pharmacol Ther 78:378–387
792 Eur J Clin Pharmacol (2018) 74:785–792
